I. MODIFIED AGREEMENTS
Biotech Co.*
(Country; Symbol)		 Pharma Co.
(Country)		 Change from original agreement Terms/Details (Date)
Ablynx (Belgium; BR:ABLX) Wyeth Pharmaceuticals Extended agreement to discover and develop novel nanobody-based therapeutics against TNF-alpha Wyeth has exclusive rights to develop and commercialize the anti-TNF-alpha nanobodies developed under the collaboration; Ablynx receives research funding and would be entitled to future milestone payments and royalties (12/20)
Akela Pharma Inc. (Canada; TSX:AKL) Janssen Pharmaceutica NV (unit of Johnson & Johnson) Extended agreement of a licensed and development deal for Fentanyl Taifun to include Canada The existing agreement already covers the European Union, Eastern Europe, Russia, the Middle East and Africa (1/3)
Centocor Inc. (unit of Johnson & Johnson) Schering-Plough Corp. Distribution agreement for Remicade and golimumab was revised to extend the duration of Schering-Plough's rights Schering-Plough can now exclusively market Remicade in its territories beyond 2014, which will match the current duration of marketing rights for golimumab (12/21)
Exelixis Inc. (EXEL) Bristol-Myers Squibb Co. Exercised option to develop and commercialize Exelixis' compound XL139 in the U.S. The decision triggered a $20M payment to Exelixis; the original deal was signed in January 2007 (1/22)
Innate Pharma SAS (France; SSE:INPH) Novo Nordisk A/S (Denmark) Refocused research collaboration on inflammation The companies signed the agreement in April 2006; it was aimed at developing new drugs targeting natural killer cells for the treatment of cancer, autoimmune disorders and infectious diseases (2/6**)
NicOx SA (France; PARIS:COX) Pfizer Inc. Extended collaboration for NicOx's nitric oxide-donating technology to be used for drug discovery research in ophthalmology The collaboration is extended for one year, resulting in €3M ($4.4M) in research funding and prolongs Pfizer's option to license resulting compounds until May 2009 (1/8)
II. TERMINATED AGREEMENTS
IDM Pharma Inc. (IDMI) Sanofi-Aventis Group (France) Terminated agreement for the Phase II-stage Uvidem for melanoma IDM Pharma regains all rights (12/31)
Inspire Pharmaceuticals Inc. (ISPH) FAES Farma SA (Spain) Terminated agreement for bilastine for allergic rhinitis The decision came as a result of the FDA requesting an expanded QT/QTc comparative trial in addition to the European Phase III studies already done (1/14)
Medivir AB (Sweden; SSE:MVIRB) Presidio Pharmaceuticals Inc. Agreement to return rights to MIV-310, which allows Medivir to transfer the full license to the compound and intellectual property to Beijing Mefuvir Medicinal Technology Co. Ltd., of China Medivir licensed the product to Presidio in a December 2006 deal (12/21)
Notes:

# The information in the chart does not cover agreements between biotech companies or agricultural agreements.

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

BR = Brussels Stock Exchange; SSE = Stockholm Stock Exchange; TSX = Toronto Stock Exchange.